메뉴 건너뛰기




Volumn 10, Issue , 2017, Pages 47-55

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome

Author keywords

Canagliflozin; Metabolic syndrome; Sodium glucose co transporter 2; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL;

EID: 85012033949     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S126291     Document Type: Article
Times cited : (13)

References (37)
  • 1
    • 17144380822 scopus 로고    scopus 로고
    • The metabolic syndrome
    • Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–1428.
    • (2005) Lancet , vol.365 , Issue.9468 , pp. 1415-1428
    • Eckel, R.H.1    Grundy, S.M.2    Zimmet, P.Z.3
  • 2
    • 84923190501 scopus 로고    scopus 로고
    • Metabolic syndrome: A closer look at the growing epidemic and its associated pathologies
    • O’Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015;16(1):1–12.
    • (2015) Obes Rev , vol.16 , Issue.1 , pp. 1-12
    • O’Neill, S.1    O’Driscoll, L.2
  • 3
    • 84929501636 scopus 로고    scopus 로고
    • Prevalence of the metabolic syndrome in the United States, 2003–2012
    • Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA. 2015; 313(19):1973–1974.
    • (2015) JAMA , vol.313 , Issue.19 , pp. 1973-1974
    • Aguilar, M.1    Bhuket, T.2    Torres, S.3    Liu, B.4    Wong, R.J.5
  • 4
    • 84893193652 scopus 로고    scopus 로고
    • The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: A collaborative analysis of ten large cohort studies
    • van Vliet-Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014;14:9.
    • (2014) BMC Endocr Disord , vol.14 , pp. 9
    • Van Vliet-Ostaptchouk, J.V.1    Nuotio, M.L.2    Slagter, S.N.3
  • 5
    • 84958921233 scopus 로고    scopus 로고
    • Canagliflozin: A sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus
    • Rosenthal N, Meininger G, Ways K, et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci. 2015;1358(1):28–43.
    • (2015) Ann N Y Acad Sci , vol.1358 , Issue.1 , pp. 28-43
    • Rosenthal, N.1    Meininger, G.2    Ways, K.3
  • 6
    • 84874291673 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
    • Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372–382.
    • (2013) Diabetes Obes Metab , vol.15 , Issue.4 , pp. 372-382
    • Stenlöf, K.1    Cefalu, W.T.2    Kim, K.A.3
  • 7
    • 84893299467 scopus 로고    scopus 로고
    • Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: Findings from the 52-week CANTATAM study
    • Stenlöf K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATAM study. Curr Med Res Opin. 2014;30(2):163–175.
    • (2014) Curr Med Res Opin , vol.30 , Issue.2 , pp. 163-175
    • Stenlöf, K.1    Cefalu, W.T.2    Kim, K.A.3
  • 8
    • 84887997289 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial
    • Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582–2592.
    • (2013) Diabetologia , vol.56 , Issue.12 , pp. 2582-2592
    • Lavalle-González, F.J.1    Januszewicz, A.2    Davidson, J.3
  • 9
    • 84888059660 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial
    • Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67(12):1267–1282.
    • (2013) Int J Clin Pract , vol.67 , Issue.12 , pp. 1267-1282
    • Wilding, J.P.1    Charpentier, G.2    Hollander, P.3
  • 10
    • 84898791440 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
    • Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014; 16(5):467–477.
    • (2014) Diabetes Obes Metab , vol.16 , Issue.5 , pp. 467-477
    • Forst, T.1    Guthrie, R.2    Goldenberg, R.3
  • 11
    • 84930844091 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes
    • Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38(3):403–411.
    • (2015) Diabetes Care , vol.38 , Issue.3 , pp. 403-411
    • Neal, B.1    Perkovic, V.2    De Zeeuw, D.3
  • 12
    • 84942320701 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: A randomized, controlled trial
    • Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: a randomized, controlled trial. Diabetes Ther. 2015;6(3):289–302.
    • (2015) Diabetes Ther , vol.6 , Issue.3 , pp. 289-302
    • Fulcher, G.1    Matthews, D.R.2    Perkovic, V.3
  • 13
    • 84955184453 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes
    • Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18(1):82–91.
    • (2016) Diabetes Obes Metab , vol.18 , Issue.1 , pp. 82-91
    • Fulcher, G.1    Matthews, D.R.2    Perkovic, V.3
  • 14
    • 84962069581 scopus 로고    scopus 로고
    • Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy in drug-naive type 2 diabetes
    • Rosenstock J, Chuck L, Gonzalez-Ortiz M, Merton K, Craig J, Capuano G. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy in drug-naive type 2 diabetes. Diabetes Care. 2016;39(3):353–362.
    • (2016) Diabetes Care , vol.39 , Issue.3 , pp. 353-362
    • Rosenstock, J.1    Chuck, L.2    Gonzalez-Ortiz, M.3    Merton, K.4    Craig, J.5    Capuano, G.6
  • 15
    • 84973549996 scopus 로고    scopus 로고
    • Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin
    • Rodbard HW, Seufert J, Aggarwal N, et al. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes Obes Metab. 2016;18(8):812–819.
    • (2016) Diabetes Obes Metab , vol.18 , Issue.8 , pp. 812-819
    • Rodbard, H.W.1    Seufert, J.2    Aggarwal, N.3
  • 16
    • 84876311251 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
    • Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15(5):463–473.
    • (2013) Diabetes Obes Metab , vol.15 , Issue.5 , pp. 463-473
    • Yale, J.F.1    Bakris, G.2    Cariou, B.3
  • 17
    • 84912527805 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
    • Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16(10):1016–1027.
    • (2014) Diabetes Obes Metab , vol.16 , Issue.10 , pp. 1016-1027
    • Yale, J.F.1    Bakris, G.2    Cariou, B.3
  • 18
    • 84880543926 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: A randomized trial
    • Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract. 2013;41(2):72–84.
    • (2013) Hosp Pract , vol.41 , Issue.2 , pp. 72-84
    • Bode, B.1    Stenlöf, K.2    Sullivan, D.3    Fung, A.4    Usiskin, K.5
  • 19
    • 84964240560 scopus 로고    scopus 로고
    • Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes
    • Bode B, Stenlöf K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes. Diabetes Obes Metab. 2015;17(3):294–303.
    • (2015) Diabetes Obes Metab , vol.17 , Issue.3 , pp. 294-303
    • Bode, B.1    Stenlöf, K.2    Harris, S.3
  • 20
    • 84884167643 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
    • Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; 382(9896):941–950.
    • (2013) Lancet , vol.382 , Issue.9896 , pp. 941-950
    • Cefalu, W.T.1    Leiter, L.A.2    Yoon, K.H.3
  • 21
    • 84940110139 scopus 로고    scopus 로고
    • Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: A randomized, double-blind, phase 3 study
    • Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38(3): 355–364.
    • (2015) Diabetes Care , vol.38 , Issue.3 , pp. 355-364
    • Leiter, L.A.1    Yoon, K.H.2    Arias, P.3
  • 22
    • 84891784200 scopus 로고    scopus 로고
    • Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week, randomized trial
    • Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care. 2013;36(9):2508–2515.
    • (2013) Diabetes Care , vol.36 , Issue.9 , pp. 2508-2515
    • Schernthaner, G.1    Gross, J.L.2    Rosenstock, J.3
  • 23
    • 84919491900 scopus 로고    scopus 로고
    • Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea
    • Ji L, Han P, Liu Y, et al. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. Diabetes Obes Metab. 2015;17(1):23–31.
    • (2015) Diabetes Obes Metab , vol.17 , Issue.1 , pp. 23-31
    • Ji, L.1    Han, P.2    Liu, Y.3
  • 25
    • 84957709696 scopus 로고    scopus 로고
    • Sodium-glucose cotransporter inhibitors: Effects on renal and intestinal glucose transport: From bench to bedside
    • Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care. 2015;38(12):2344–2353.
    • (2015) Diabetes Care , vol.38 , Issue.12 , pp. 2344-2353
    • Mudaliar, S.1    Polidori, D.2    Zambrowicz, B.3    Henry, R.R.4
  • 26
    • 84919999219 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1):140–149.
    • (2015) Diabetes Care , vol.38 , Issue.1 , pp. 140-149
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 27
    • 84899960517 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: A pooled analysis of clinical studies
    • Sinclair A, Bode B, Harris S, et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord. 2014; 14(1):37.
    • (2014) BMC Endocr Disord , vol.14 , Issue.1 , pp. 37
    • Sinclair, A.1    Bode, B.2    Harris, S.3
  • 28
    • 84961833550 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: A pooled analysis
    • Sinclair AJ, Bode B, Harris S, et al. Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis. J Am Geriatr Soc. 2016;64(3):543–552.
    • (2016) J am Geriatr Soc , vol.64 , Issue.3 , pp. 543-552
    • Sinclair, A.J.1    Bode, B.2    Harris, S.3
  • 29
    • 84977071302 scopus 로고    scopus 로고
    • Impact of age and estimated glomerular filtration rate on the glycaemic efficacy and safety of canagliflozin: A pooled analysis of clinical studies
    • Gilbert RE, Weir MW, Fioretto P, et al. Impact of age and estimated glomerular filtration rate on the glycaemic efficacy and safety of canagliflozin: a pooled analysis of clinical studies. Can J Diabetes. 2016;40(3): 247–257.
    • (2016) Can J Diabetes , vol.40 , Issue.3 , pp. 247-257
    • Gilbert, R.E.1    Weir, M.W.2    Fioretto, P.3
  • 30
    • 84940775310 scopus 로고    scopus 로고
    • The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus
    • Gavin JR III, Davies MJ, Davies M, Vijapurkar U, Alba M, Meininger G. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2015;31(9):1693–1702.
    • (2015) Curr Med Res Opin , vol.31 , Issue.9 , pp. 1693-1702
    • Gavin, J.R.1    Davies, M.J.2    Davies, M.3    Vijapurkar, U.4    Alba, M.5    Meininger, G.6
  • 31
    • 84964986253 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin in type 2 diabetes patients of different ethnicity
    • Davidson JA, Aguilar R, Lavalle González FJ, et al. Efficacy and safety of canagliflozin in type 2 diabetes patients of different ethnicity. Ethn Dis. 2016;26(2):221–228.
    • (2016) Ethn Dis , vol.26 , Issue.2 , pp. 221-228
    • Davidson, J.A.1    Aguilar, R.2    Lavalle González, F.J.3
  • 32
    • 84925345083 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus
    • Wilding JPH, Blonde L, Leiter LA, et al. Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. J Diabetes Complications. 2015;29(3):438–444.
    • (2015) J Diabetes Complications , vol.29 , Issue.3 , pp. 438-444
    • Wilding, J.1    Blonde, L.2    Leiter, L.A.3
  • 33
    • 84961223678 scopus 로고    scopus 로고
    • Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome
    • Rahman A, Kittikulsuth W, Fujisawa Y, et al. Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. J Hypertens. 2016;34(5):893–906.
    • (2016) J Hypertens , vol.34 , Issue.5 , pp. 893-906
    • Rahman, A.1    Kittikulsuth, W.2    Fujisawa, Y.3
  • 34
    • 84885476895 scopus 로고    scopus 로고
    • Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
    • Tahara A, Kurosaki E, Yokono M, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715(1–3):246–255.
    • (2013) Eur J Pharmacol , vol.715 , Issue.1-3 , pp. 246-255
    • Tahara, A.1    Kurosaki, E.2    Yokono, M.3
  • 35
    • 83655167071 scopus 로고    scopus 로고
    • Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats
    • Thomas L, Grempler R, Eckhardt M, et al. Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes Metab. 2012;14(1):94–96.
    • (2012) Diabetes Obes Metab , vol.14 , Issue.1 , pp. 94-96
    • Thomas, L.1    Grempler, R.2    Eckhardt, M.3
  • 36
    • 34548500797 scopus 로고    scopus 로고
    • Challenges in developing therapies for the metabolic syndrome
    • Matfin G. Challenges in developing therapies for the metabolic syndrome. Br J Diabetes Vasc Dis. 2007;7(4):152–156.
    • (2007) Br J Diabetes Vasc Dis , vol.7 , Issue.4 , pp. 152-156
    • Matfin, G.1
  • 37
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22):2117–2128.
    • (2015) N Engl J Med , vol.373 , Issue.22 , pp. 2117-2128
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.